SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Files An 8-K Results of Operations and Financial Condition

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02 Results of Operations and Financial Condition

On March 6, 2017, SciClone Pharmaceuticals, Inc. issued a press
release announcing final financial results for the fourth quarter
and calendar year ended December 31, 2016. The press release is
attached hereto as Exhibit 99.1 and is incorporated by reference
herein in its entirety.

The information in Item 2.02 of this Current Report on Form 8-K,
including Exhibit 99.1 to this Current Report on Form 8-K, shall
not be deemed to be filed for purposes of Section 18 of the
Securities and Exchange Act of 1934, as amended (the Exchange
Act), or incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such a
filing.

Item 9.01 Financial Statements and Exhibits

(d) The following exhibits are filed herewith:

Exhibit 99.1

Press release dated March 6, 2017.


About SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company’s development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Recent Trading Information

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) closed its last trading session 00.00 at 10.00 with 210,286 shares trading hands.

An ad to help with our costs